Results 81 to 90 of about 5,892 (166)

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

PLoS ONE, 2017
AimsSeveral studies reported treatment benefits of tolvaptan in patients with congestive heart failure (CHF). However, the optimal dosage remains unclear.
Mei-Yi Wu, Tzu-Ting Chen, Ying-Chun Chen, Der-Cherng Tarng, Yun-Chun Wu, Hsien-Ho Lin, Yu-Kang Tu   +6 more
doaj   +1 more source

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)

ESC Heart Failure, 2020
Aims Hyponatremia is associated with poorer outcomes and diuretic response in patients hospitalized for heart failure. This study compared a tolvaptan‐based vs.
Tien M.H. Ng, Luanda P. Grazette, Michael W. Fong, Andrew J. Yoon, Mimi Lou, Allen Kuo, Rani Y. Upadhyay, Emily E. Han, Anilkumar Mehra, Uri Elkayam   +9 more
doaj   +1 more source

Long-term low-dose tolvaptan efficacy and safety in SIADH

, 2023
Purpose: Tolvaptan, a selective vasopressin V2-receptor antagonist, is approved for the treatment of SIADH-related hyponatremia, but its use is limited. The starting dose is usually 15 mg/day, but recent clinical experience suggests a lower starting dose
Irene Gagliardi, Ambrosio, Maria Rosaria, Marta Bondanelli, Ludovica Aliberti, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Zatelli, Maria Chiara, Bondanelli, Marta, Aliberti, Ludovica, Gagliardi, Irene   +9 more
core   +1 more source

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report

Case Reports in Nephrology and Dialysis, 2018
A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years.
Kyohei Kunizawa, Junichi Hoshino, Hiroki Mizuno, Tatsuya Suwabe, Keiichi Sumida, Masahiro Kawada, Masayuki Yamanouchi, Akinari Sekine, Noriko Hayami, Rikako Hiramatsu, Eiko Hasegawa, Naoki Sawa, Kenmei Takaichi, Shigeru Shibata, Yoshifumi Ubara   +14 more
doaj   +1 more source

SHORT COMMUNICATION Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes Running Title: Tolvaptan Disposition and DDIs in SCHH

, 2020
: Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-
K L R, J R S, ( Y L
core  

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial

, 2017
Satoru Muto,1 Tadashi Okada,2 Moriyoshi Yasuda,3 Hidetsugu Tsubouchi,4 Koji Nakajima,4 Shigeo Horie1,5 1Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, 2Department of Clinical Development ...
Nakajima K, Yasuda M, Horie S, Muto S, Tsubouchi H, Okada T   +5 more
core  

Short-term efficacy and safety of tolvaptan in patients with left ventricular assist devices

, 2020
Copyright © 2019 by the ASAIO Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist devices (LVADs) is unknown.
Takeo Fujino, Teruhiko Imamura, Kalantari, Sara, Sayer, Gabriel, Sara Kalantari, Nitasha Sarswat, Nguyen, Ann, Nikhil Narang, Jeevanandam, Valluvan, Daisuke Nitta, Chung, Ben, Labuhn, Colleen, Gabriel Sayer, Nitta, Daisuke, Gene Kim, Bryan Smith, Colleen LaBuhn, Uriel, Nir, Raikhelkar, Jayant, Smith, Bryan, Narang, Nikhil, Sarswat, Nitasha, Daniel Rodgers, Rodgers, Daniel, Kim, Gene, Ben Chung, Imamura, Teruhiko, Nir Uriel, Valluvan Jeevanandam, Ann Nguyen, Jayant Raikhelkar, Fujino, Takeo   +31 more
core   +1 more source

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

, 2011
Summary Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models.
Vicente E. Torres, Grantham, Jared J., Eiji Higashihara, Torres, Vicente E., Chapman, Arlene B., Krasa, Holly B., Kikuo Nutahara, Higashihara, Eiji, Horie, Shigeo, Bae, Kyongtae, Kyongtae Bae, Jared J. Grantham, Watnick, Terry J., Arlene B. Chapman, Terry J. Watnick, Nutahara, Kikuo, Ouyang, John, Shigeo Horie, John Ouyang, Holly B. Krasa, Czerwiec, Frank S., Frank S. Czerwiec   +21 more
core   +1 more source

Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India

Heart Views, 2014
Background: In acute decompensated heart failure (ADHF), diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. Vasopressin mediates fluid retention in heart failure.
Soumya Patra, Basant Kumar, Kaushal K Harlalka, Apoorva Jain, H M Bhanuprakash, K S Sadananda, Harsha Basappa, K Santhosh, K S Rajith, K S Bharathi, C N Manjunath   +10 more
doaj   +1 more source

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis

Frontiers in Pharmacology
Background: Tolvaptan, a selective vasopressin V2-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15 ...
Hongzhong Liu, Yongfeng Wang, Tao Liu, Yingxuan Chen, Xin Zheng, Ming Liu, Qian Zhao, Minde Zeng, Ji Jiang, Yimin Mao, Pei Hu   +10 more
doaj   +1 more source